# Bionsight

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/bionsight

- Industry: Biotechnology
- Headquarters: Chuncheon, South Korea
- Website: www.bionsight.com
- Total disclosed funding: $15M
- Investors on record: 3

## About

Based in Seoul, South Korea, and founded in 2019, Bionsight Inc. operates as a drug discovery company that uses artificial intelligence for target identification and off-target profiling within the drug development process. In August 2023, Bionsight, Inc. raised KRW 5.5 billion in series A funding led by SV Investment, DSC Investment, and Schmidt. As of 2023, the company is led by its CEO Heejung Yang.

The drug discovery company uses an artificial intelligence-based "Javelin" chemo proteomics platform that conducts pharmaceutical development processes, which include target verification, de novo drug design, and results analysis.

The company plans to use the August 2023 funding to purchase production equipment and hire research personnel.

## Funding rounds

- Round, Nov 3, 2026, $11M
- Series A, Aug 16, 2023, $4.1M — DSC Investment, SV Investment, Schmidt

## Investors

- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A
- SV Investment (https://capitalatlas.ai/funds/sv-investment) — Series A
- Schmidt (https://capitalatlas.ai/funds/schmidt) — Series A